Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Lymphoma, Non-Hodgkin 1Leukemia, B-Cell 1B-cell Malignancies 1

Interventions

Cyclophosphamide 18ofatumumab 14fludarabine 12Rituximab 11ibrutinib 10fludarabine phosphate 9acalabrutinib 7obinutuzumab 6Lenalidomide 6Bendamustine Hydrochloride 6venetoclax 5pirtobrutinib 4Vincristine 4Mesna 4Melphalan 4Immunotherapy, Adoptive 4Whole-Body Irradiation 3Mycophenolic Acid 3Chlorambucil 3Bortezomib 3Alemtuzumab 3spebrutinib 2navitoclax 2idelalisib 2Tacrolimus 2Tablets 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2KW-2478 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, B-Cell × tirabrutinib × Clear all
NCT01659255 2021-03-16

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Gilead Sciences

Phase 1 Completed
90 enrolled 27 charts
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡